Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cypress Pharmaceutical's new drug application for Zutripro (hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine HCl) oral solution (CIII) and Rezira (hydrocodone bitartrate and pseudoephedrine HCl) oral solution (CIII) received the US Food and Drug Administration (FDA) approval.
Subscribe to our email newsletter
Zutripro oral solution and Rezira oral solution, to be marketed by Cypress Pharma’s subsidiary Hawthorn Pharmaceuticals, are indicated for the treatment of cough and other symptoms linked with common cold.
The company expects to start shipping the product soon.
Hawthorn Pharma Sales EVP Chris Smith said with Zutripro and Rezira oral solutions, healthcare practitioners finally have more options when treating patients suffering from a cough and symptoms associated with the common cold.
"Additionally, Zutripro and Rezira both contain a decongestant which is very beneficial considering the fact that one of the most common symptoms of the common cold is nasal congestion," Smith said.